TMDX Q4 2020 Earnings — TransMedics Group, Inc. Revenue & Financial Results | Market Cap Arena

TMDXTransMedics Group, Inc.

$5B

Q4 2020 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$8M+25.9% YoY

Gross Profit

$5M63.3% margin

Operating Income

-$6M-77.3% margin

Net Income

-$6M-82.7% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+7.6%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$698,000

Balance Sheet

Total Assets

$152M

Total Liabilities

$48M

Stockholders' Equity

$104M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$6M	+25.9%
Gross Profit	$5M	$4M	+29.1%
Operating Income	-$6M	-$9M	+32.2%
Net Income	-$6M	-$9M	+31.2%

Revenue Segments

Ocs Lung Product

$3M41%

Ocs Heart Product

$2M32%

Ocs Liver Product

$2M28%

Geographic Segments

UNITED STATES

$6M52%

Non Us And Uk

$5M48%